Device type · MXA
System, Test, Breath Nitric Oxide
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
MXA
Clinical Chemistry
Device class
Class II
FDA decisions since 2015
8
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- System, Test, Breath Nitric Oxide
- Product code
- MXA
- Device class
- Class II
- Review panel
- Clinical Chemistry
- Regulation
- 21 CFR 862.3080
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for MXA
Latest FDA decisions
K251674 · Decided Nov 26, 2025 · 180 days after receipt
Device type: System, Test, Breath Nitric Oxide (MXA) · Laboratory Medicine & Pathology
- Vivatmo pro-S510(k)
Bosch Healthcare Solutions GmbH
K243926 · Decided Sep 11, 2025 · 265 days after receipt
Device type: System, Test, Breath Nitric Oxide (MXA) · Laboratory Medicine & Pathology
- Vivatmo pro510(k)
Bosch Healthcare Solutions GmbH
K233775 · Decided Feb 22, 2024 · 90 days after receipt
Device type: System, Test, Breath Nitric Oxide (MXA) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
No reports to chart for this view.
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-1284-2021 · Started Feb 26, 2021
Reason given: Erroneously high FeNO levels which may contribute to premature discontinuation of effective asthma treatment and persistent underlying disease. Two issues affecting the FeNO readings: 1) Drift in the calibration gases and 2) Software error. Each of these issues can cause FeNO scores/results to be erroneously high.
Cause as FDA categorized it: Process control
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.